| Bioactivity | MGS0274, an ester-based lipophilic prodrug of a metabotropic glutamate (mGlu)2 and mGlu3 receptor agonist MGS0008, shows improved oral bioavailability. MGS0274 has the potential for the research of schizophrenia[1][2]. |
| Name | MGS0274 |
| CAS | 1501974-69-1 |
| Formula | C21H32FNO7 |
| Molar Mass | 429.48 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Urabe H, et al. Discovery of MGS0274, an ester prodrug of a metabotropic glutamate receptor 2/3 agonist with improved oral bioavailability [published online ahead of print, 2020 Jul 5]. Eur J Med Chem. 2020;203:112521. [2]. Kinoshita K, et al. Preclinical disposition of MGS0274 besylate, a prodrug of a potent group II metabotropic glutamate receptor agonist MGS0008 for the treatment of schizophrenia. Pharmacol Res Perspect. 2019;7(5):e00520. Published 2019 Sep 13. |